Celsion Corp (CLSN)

$ 1.08
-0.02 (-1.82%)
Buy
Symbol CLSN
Price $ 1.08
Beta 2.042
Volume Avg. 13.98M
Market Cap 0.09B
Shares () -
52 Week Range 0.43-6.5
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -110.62% Strong Sell
ROA -57.25% Strong Sell
Operating Margin -
Debt / Equity 101.64% Buy
P/E -
P/B 1.98 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Top Penny Stocks Today? 3 Cheap Stocks to Watch

Top Penny Stocks Today? 3 Cheap Stocks to Watch

Penny stocks are in focus once again as the hype around Doge Coin ramps up The post Top Penny Stocks Today? 3 Cheap Stocks to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. ...

PennyStocks
CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

Lawrenceville, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purcha... ...

GlobeNewsWire
Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates

Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates

Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Women's Cancer. GEN-1 is a DNA-mediated interl... ...

Benzinga
Why VTSI Stock AND CLSN Stock Are Trading Lower Today

Why VTSI Stock AND CLSN Stock Are Trading Lower Today

Virtra Inc (NASDAQ: VTSI) shares are trading lower by 22% Wednesday after the company priced a registered direct offering at $6 per share. VirTra is engaged in the sale and development of the judgmental use of force training simulators and firearms t... ...

Benzinga
Celsion Corporation (CLSN) CEO Michael Tardugno on Q4 2020 Results - Earnings Call Transcript

Celsion Corporation (CLSN) CEO Michael Tardugno on Q4 2020 Results - Earnings Call Transcript

Celsion Corporation (CLSN) CEO Michael Tardugno on Q4 2020 Results - Earnings Call Transcript ...

Seeking Alpha
Celsion Corporation Reports 2020 Financial Results and Provides Business Update

Celsion Corporation Reports 2020 Financial Results and Provides Business Update

Entered 2021 with a Focus on Cancer Immunotherapy and  Next-Generation Infectious Vaccines and a Strong Balance Sheet ...

GlobeNewsWire
Earnings Previews: FedEx, Luminar, Nike, Celsion

Earnings Previews: FedEx, Luminar, Nike, Celsion

Wednesday afternoon's and Thursday morning's noteworthy earnings reports were included in our Tuesday preview covering scheduled reports from electric pickup maker Lordstown Motors, cannabis producers Sundial Growers and Hexo, and discount retailer D... ...

24/7 Wall Street
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on F...

LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference ... ...

GlobeNewsWire
8 Biotech Penny Stocks for Investors to Watch

8 Biotech Penny Stocks for Investors to Watch

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider. ...

InvestorPlace
Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately. ...

Zacks Investment Research

About


Michael Tardugno
Healthcare
Biotechnology
Nasdaq Capital Market

Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.